Saturday 17 October 2026
Export NAGE’s income statement to Excel — free account
Niagen Bioscience, Inc.
NAGE Healthcare Biotechnology
Niagen Bioscience, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $129.4 million, up 29.9% from fiscal 2024. In the quarter to June 2026, revenue fell 4.28%, EPS fell 80.0% and free cash flow grew 140.6%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
2.49
0.09
−3.49%
Follow NAGE
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
6 | 8 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 4 |
P/E ratio |
27.65 | 51.40 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
10.54 | 9.82 | (0.61) | (1.20) | 1.95 | 3.17 | 2.34 | 3.33 | 16.85 | 5.40 |
P/S ratio |
3.89 | 4.05 | 1.28 | 1.64 | 3.73 | 4.95 | 5.31 | 5.98 | 13.36 | 5.94 |
P/FCF ratio |
38.17 | 33.74 | 15.42 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
3.42 | (1.31) | (7.40) | (8.83) | (7.84) | (12.05) | (11.01) | (6.88) | 6.80 | (5.10) |
P/Operating CF |
741.64 | 46.97 | 165.22 | (359.27) | (50.82) | 13,323.71 | (403.13) | (36.73) | (75.18) | 672.93 |
Beneish M-Score |
(1.55) | (2.36) | (3.96) | (2.04) | (1.81) | (3.39) | (3.97) | (4.27) | (3.29) | 0.15 |
P/B ratio |
6.58 | 8.75 | 3.77 | 4.11 | 7.92 | 17.85 | 12.03 | 6.94 | 5.26 | 12.90 |
Price to Tangible BV |
7.11 | 8.82 | 3.84 | 4.21 | 8.14 | 19.11 | 12.85 | 7.36 | 5.43 | 13.56 |
EV/Sales |
3.40 | 3.62 | 0.98 | 1.38 | 3.40 | 4.70 | 4.95 | 5.33 | 11.32 | 5.97 |
EV/EBITDA |
25.82 | 42.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
32.63 | 29.76 | 11.49 | (6.58) | (9.48) | (26.26) | (11.20) | (8.04) | (24.48) | (44.01) |
EV/FCF |
33.40 | 30.16 | 11.76 | (6.43) | (9.32) | (25.91) | (11.09) | (7.52) | (46.13) | (27.72) |
Quick Ratio |
3.74 | 2.92 | 1.58 | 1.62 | 1.90 | 1.18 | 1.39 | 1.92 | 6.27 | 0.85 |
Current Ratio |
4.86 | 3.57 | 2.40 | 2.61 | 2.78 | 1.96 | 2.23 | 2.53 | 7.07 | 1.77 |
Net Debt/EBITDA |
(3.80) | (5.23) | 5.98 | 1.16 | 0.93 | 0.89 | 0.64 | 0.70 | 2.88 | 0.52 |
Debt/Assets |
0.00% | 0.00% | 0.02% | 0.04% | 7.18% | 0.05% | 0.04% | 0.32% | 0.49% | 1.74% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.13 | 0.00 | 0.00 | 0.01 | 0.01 | 0.03 |
Asset Turnover |
1.48 | 1.62 | 1.53 | 1.29 | 1.40 | 1.51 | 1.12 | 0.60 | 0.51 | 1.13 |
Operating CF/Net income |
0.78 | 1.42 | (1.44) | 0.91 | 0.89 | 0.53 | 0.64 | 0.63 | 0.86 | 1.00 |
Capex/Depreciation |
(0.37) | (0.18) | (0.14) | (0.32) | (0.37) | (0.13) | (0.11) | (1.72) | 6.43 | (4.11) |
Interest Coverage |
— | — | — | 6,209.33 | (492.24) | (279.63) | (36.95) | (419.90) | (107.04) | (8.72) |
| 28.35% | 22.94% | (17.29%) | (54.77%) | (112.68%) | (108.09%) | (135.01%) | (82.25%) | (35.66%) | (38.40%) | |
| 19.90% | 13.88% | (9.06%) | (29.56%) | (56.40%) | (50.70%) | (77.95%) | (63.49%) | (27.59%) | (15.21%) | |
ROIC |
86.63% | 336.73% | (306.16%) | (141.07%) | (220.84%) | 0.00% | (1,184.89%) | (441.21%) | (116.91%) | (20.93%) |
Return on Tangible Assets |
22.22% | 17.86% | (15.90%) | (52.51%) | (79.10%) | (105.15%) | (144.68%) | (129.74%) | (21.90%) | (33.87%) |
Average Days of Receivables |
27.47 | 28.47 | 22.86 | 42.97 | 28.28 | 16.59 | 17.15 | 58.25 | 91.90 | 98.59 |
Research and Development Expense of Revenue |
4.89% | 6.04% | 5.93% | 6.70% | 5.68% | 5.76% | 9.55% | 17.36% | 18.90% | 11.64% |
Selling, General and Administrative Expense of Revenue |
48.34% | 48.04% | 61.53% | 78.56% | 95.97% | 87.27% | 113.46% | 138.40% | 104.25% | 49.73% |
Intangible Assets out of Total Assets |
0.05 | 0.01 | 0.01 | 0.01 | 0.01 | 0.03 | 0.03 | 0.04 | 0.03 | 0.02 |
Share Based Compensation of Revenue |
4.69% | 3.67% | 5.69% | 7.97% | 9.18% | 11.70% | 15.49% | 20.19% | 21.72% | 5.51% |
Graham Net Nets |
0.13 | 0.10 | 0.21 | 0.18 | 0.09 | 0.04 | 0.06 | 0.11 | 0.17 | 0.05 |
Graham Number |
2.24 | 1.19 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
3.62% | 1.95% | (4.78%) | (13.87%) | (10.96%) | (6.88%) | (12.99%) | (17.78%) | (3.78%) | (2.48%) |
Free Cash Flow Yield |
2.62% | 2.96% | 6.49% | (13.11%) | (9.79%) | (3.66%) | (8.39%) | (11.85%) | (1.84%) | (3.62%) |
Revenue per Share |
1.63 | 1.31 | 1.11 | 1.03 | 1.00 | 0.97 | 0.81 | 0.57 | 0.48 | 0.58 |
Operating CF per Share |
0.17 | 0.16 | 0.09 | (0.22) | (0.36) | (0.17) | (0.36) | (0.38) | (0.22) | (0.08) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | (0.01) | 0.00 | 0.00 | (0.03) | 0.10 | (0.05) |
Free Cash Flow per Share |
0.17 | 0.16 | 0.09 | (0.22) | (0.37) | (0.18) | (0.36) | (0.41) | (0.12) | (0.12) |
Cash per Share |
0.82 | 0.59 | 0.36 | 0.29 | 0.42 | 0.27 | 0.33 | 0.41 | 1.02 | 0.04 |
Shareholders Equity per Share |
0.97 | 0.61 | 0.38 | 0.41 | 0.47 | 0.27 | 0.36 | 0.49 | 1.21 | 0.27 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.97 | 0.61 | 0.38 | 0.41 | 0.47 | 0.27 | 0.36 | 0.49 | 1.21 | 0.27 |
Free Cash Flow |
13.21 | 11.97 | 6.97 | (15.43) | (24.57) | (10.74) | (20.64) | (22.36) | (5.20) | (4.66) |
Working Capital |
76.89 | 46.15 | 28.91 | 28.70 | 31.29 | 15.74 | 18.46 | 22.09 | 49.09 | 6.87 |
Capital Expenditures |
(0.29) | (0.14) | (0.14) | (0.33) | (0.41) | (0.14) | (0.20) | (1.45) | 4.60 | (1.72) |
Net Current Asset Value |
66.93 | 41.92 | 23.03 | 21.18 | 22.79 | 10.29 | 13.72 | 21.48 | 48.29 | 5.96 |
EV/EBIT |
27.07 | 46.65 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.05 | (0.22) | 0.08 |
Price to Operating Income |
30.93 | 52.19 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.59 | 0.47 | 0.48 | 0.38 | 0.37 | 0.35 | 0.49 | 0.23 | 0.25 | 0.24 |
Cash ROIC |
9.35% | 13.19% | 12.50% | (31.41%) | (38.33%) | (32.41%) | (52.55%) | (44.78%) | (5.23%) | (38.97%) |
Accounts Receivable Turnover |
14.78 | 15.32 | 12.19 | 10.51 | 17.03 | 24.34 | 12.84 | 6.08 | 3.79 | 5.22 |
Accounts Payable Turnover |
4.79 | 4.05 | 3.29 | 2.91 | 2.61 | 2.52 | 2.14 | 2.34 | 2.21 | 1.85 |
Inventory Turnover |
3.12 | 3.21 | 2.25 | 2.07 | 2.05 | 2.07 | 2.07 | 2.21 | 1.56 | 1.40 |
Average Days of Payables |
85.23 | 81.87 | 113.90 | 120.77 | 146.55 | 143.74 | 171.21 | 224.81 | 126.58 | 193.55 |
Days of Inventory on Hand |
161.24 | 88.27 | 161.68 | 183.13 | 191.24 | 177.80 | 205.16 | 194.23 | 197.27 | 256.17 |
Average Receivables |
8.75 | 6.50 | 6.86 | 6.85 | 3.96 | 2.43 | 3.61 | 5.19 | 5.60 | 4.15 |
Average Payables |
9.66 | 9.38 | 9.96 | 10.05 | 9.93 | 9.54 | 9.59 | 6.63 | 4.85 | 6.10 |
Average Inventory |
14.81 | 11.86 | 14.60 | 14.14 | 12.64 | 11.61 | 9.89 | 7.02 | 6.85 | 8.04 |
Average Assets |
87.34 | 61.62 | 54.51 | 55.95 | 48.10 | 39.30 | 41.24 | 52.48 | 41.24 | 19.25 |
Average Common Equity |
61.31 | 37.28 | 28.56 | 30.20 | 24.08 | 18.43 | 23.81 | 40.51 | 31.90 | 7.62 |
Columns are period end dates